Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples